Skip to main content

OGS Inks Second Deal with Pfizer

NEW YORK, Jan. 7-Oxford GlycoSciences said today that it has expanded its proteomics contract with Pfizer.


OGS first struck a deal with Pfizer in 1998, a collaboration intended to identify new biomarkers and drug targets in Alzheimer's disease, arteriosclerosis and other diseases.


The disease area and financial terms of the new agreement were not disclosed.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.